Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may help doctors choose best lung cancer therapy

NCT ID NCT03289780

Knowledge-focused Sponsor: Biodesix, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This observational study tracks over 5,000 people with non-small cell lung cancer to see how doctors use the VeriStrat blood test when deciding on treatment. Researchers want to learn if the test results change what therapy patients receive and whether new experimental tests can better predict how well immunotherapy will work. The study does not test a new drug but aims to improve future treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better personalize lung cancer treatment by using blood tests to predict which therapies work best for each patient.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test a new therapy. The investigational tests are for research only and may not prove useful in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

5,006 people

The number who actually took part.

Started

Apr 2016

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Any Subject with Non-Small Cell Lung Cancer (NSCLC) at all stages with any histology.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subject must be 18 years of age or older at time of signing informed consent form (ICF). 2. A diagnosis of NSCLC. 3. Subject is willing to provide serum samples for VeriStrat testing. 4. EGFR mutation status wild-type (negative) or a tested unknown. 5. For subjects with untested/unknown EGFR status only: The subject must be willing to provide blood samples for GeneStrat testing. 6. Subject is willing to provide serum samples for research, understanding that no test results will be made available either to the subject or the treating physician. 7. Subject is able to read and understand the ICF and agrees to comply with study procedures and requirements. Exclusion Criteria: 1\. Subject's ability to understand the requirements of the protocol or to provide informed consent is impaired or subject is unwilling to comply with the protocol requirements.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer

Contacts and locations

Locations

  • Arlington Cancer Center

    Arlington, Texas, 76012, United States

  • Boca Raton Regional Hospital -Lynn Cancer Institute

    Boca Raton, Florida, 33486, United States

  • Bon Secours St. Francis Cancer Center

    Greenville, South Carolina, 29607, United States

  • Central Care Cancer Center

    Bolivar, Missouri, 65613, United States

  • Christus Health

    Shreveport, Louisiana, 71105, United States

  • Clinical Research Associates

    Lake Success, New York, 11042, United States

  • Eastern Connecticut Hematology and Oncology Associates

    Norwich, Connecticut, 06360, United States

  • Edward-Elmhurst Healthcare

    Naperville, Illinois, 60540, United States

  • Essex Oncology

    Belleville, New Jersey, 07109, United States

  • Franciscan Health Woodland Cancer Center

    Michigan City, Indiana, 46360, United States

  • Franciscan St. Francis Health

    Indianapolis, Indiana, 46237, United States

  • Gettysburg Cancer Center

    Gettysburg, Pennsylvania, 17325, United States

  • Hematology and Oncology Associates - Mercy Medical Center

    Canton, Ohio, 44708, United States

  • Highlands Oncology Group

    Fayetteville, Arkansas, 72703, United States

  • Huntsman Cancer Institute

    Salt Lake City, Utah, 84112, United States

  • Illinois Cancer Care

    Peoria, Illinois, 61615, United States

  • JPS Health Network, JPS Center for Cancer Care

    Fort Worth, Texas, 76104, United States

  • Lake City Cancer Care, LLC

    Lake City, Florida, 32024, United States

  • Leo W. Jenkins Cancer Center - East Carolina University

    Greenville, North Carolina, 27834, United States

  • Lewis & Faye Manderson Cancer Center at DCH Regional Medical Center

    Tuscaloosa, Alabama, 35401, United States

  • Mercy Medical

    Springfield, Missouri, 65804, United States

  • NYU Laura & Isaac Perlmutter Cancer Center

    New York, New York, 10016, United States

  • Nebraska Methodist Hospital

    Omaha, Nebraska, 68114, United States

  • New York Oncology Group

    Albany, New York, 12206, United States

  • North Mississippi Medical Center - Hematology and Oncology Clinic

    Tupelo, Mississippi, 38801, United States

  • Northwest Medical Specialties, PLLC

    Tacoma, Washington, 98405, United States

  • Oncology Specialties, PC; Clearview Cancer Institute

    Huntsville, Alabama, 35805, United States

  • Oregon Oncology Specialists (QCCA)

    Salem, Oregon, 97301, United States

  • Peace Health

    Bellingham, Washington, 982256, United States

  • Phelps County Regional Medical Center

    Rolla, Missouri, 65401, United States

  • Ponchartrain Cancer Center

    Covington, Louisiana, 70433, United States

  • Scott & White Memorial Hospital and Clinic

    Temple, Texas, 76508, United States

  • South Eastern Regional Medical Center

    Newnan, Georgia, 30265, United States

  • South Georgia Medical Center

    Valdosta, Georgia, 31602, United States

  • Southeastern Medical Oncology

    Goldsboro, North Carolina, 27534, United States

  • St. Bernards Cancer Center Hematology / Oncology

    Jonesboro, Arkansas, 72401, United States

  • Summit Cancer Care

    Savannah, Georgia, 31405, United States

  • The Center for Cancer and Blood Disorders

    Fort Worth, Texas, 76104, United States

  • Tri-County Hematology & Oncology Associates

    Massillon, Ohio, 44646, United States

  • University of North Carolina

    Chapel Hill, North Carolina, 27517, United States

  • Valley Medical Oncology Consultants

    Pleasanton, California, 94588, United States

  • Virginia Cancer Institute

    Richmond, Virginia, 23230, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.